NeuBase Therapeutics Inc (NASDAQ:NBSE) announced a broad set of preclinical safety and efficiency data for its Stealth Editors development program, demonstrating the ability to achieve gene editing with a non-immunogenic system.

• The data showed a dose-dependent increase in the correction of the gene mutation based on the expression of the new functional fluorescent protein compared with various controls, highlighting a titratable increase in efficiency with which the Stealth Editors can engage the genome to harness the cell's machinery to correct the mutation.
• The results show that human peripheral blood mononuclear cells treated with a Stealth Editor did not impact cell viability. In addition, there was no cellular immune response for the Stealth Editor-treated cells compared with the control (PBS) across the five cytokines measured, in direct juxtaposition to the positive controls, which elicited a strong cytokine response.
• Stealth Editors can be encapsulated via established lipid nanoparticle technologies promising a non-immunogenic delivery solution and a de-risked pathway to address therapeutic targets in the liver.
• The company plans to present additional data showcasing the gene-editing capabilities of Stealth Editors throughout the remainder of 2023, including initial non-human primate and mouse data.

Price Action: NBSE shares are up 6.93% at $0.20 at the last check Monday.

Now Read: Nvidia Analyst Lifts Price Target Ahead Of Q1 Results: 'Should Warrant A Meaningful Premium vs Semiconductor Peers'